Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation  + (Death n=1, Disease progression n=2)
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (Death n=1, disease progression n=1)
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (Death n=2, disease progression n=1)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Did not complete salivary dosimetry measurements)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Did not complete salivary dosimetry measurements)
• Jacot et al. (2016): Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study  + (Did not receive allocated intervention (Withdrew from study, adverse event))
• Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer  + (Did not receive allocated intervention (no … Did not receive allocated intervention (not to accept contributing): n=1</br>Lost to follow-up: discontinued tablets (n=1); discontinued radiation due to individual preferences: n=4</br></br>Inconsistencies in the number of drop-outs in the selenium arm: flowchart reports analyzed n=33 from n=42, but only reports drop-out reasons for n=6 (reasons missing n=3); table of baseline characteristics reports data of n=37eline characteristics reports data of n=37)
• Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer  + (Did not receive allocated intervention (not to accept contributing): n=4 Lost to follow-up: discontinued radiation due to individual preferences: n=4)
• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Did not receive the prescribed doses: n=2 because of intense mucositis and n=1 because of death caused by tumor progression)
• Jacot et al. (2016): Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study  + (Did not received allocated intervention (Withdrew from study, adverse event, other))
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Died during the course of radiation)
• Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study  + (Died, n = 4 Refused to continue chemotherapy due to inadequate control of nausea and vomiting, n = 2)
• Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study  + (Died, n = 4 Refused to continue chemotherapy due to inadequate control if nausea and vomiting, n = 2 No reporting back for second cycle, n = 2)
• Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study  + (Died: n = 4, Drop out during second cycle despite adequate control: n = 2, No reporting back for second cycle, n = 2)
• Yekta et al. (2012): Ginger as a miracle against chemotherapy-induced vomiting  + (Discontinuation of Chemotherapy, lack of compliance or death)
• Yekta et al. (2012): Ginger as a miracle against chemotherapy-induced vomiting  + (Discontinuation of Chemotherapy, lack of compliance or death)
• Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial  + (Discontinued after THC:CBD (n = 4): Death (n = 1); failure to comply (n = 1); chemotherapy stopped (n = 1); patient preference (n = 1))
• Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial  + (Discontinued after placebo (n = 2): chemotherapy stopped (n = 1); patient preference (n = 1))
• Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy  + (Discontinued guarana: n = 2 - Palpitations … Discontinued guarana: n = 2</br>- Palpitations: n = 1 </br></br>- Patient discontinued medication due to herpes zoster: n = 1 </br></br>Excluded for forgetting to take more than 1 pill: n = 5</br></br></br>Note: Time of Drop-Outs unclear, since all patients are noted to start placebo but drop-out occured for guaranat placebo but drop-out occured for guarana)
• Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy  + (Discontinued placebo: n = 2, - Rash: n = 1, - Palpitations: n = 1 Excluded for forgetting to take more than 1 pill: n = 6 Note: Time of Drop-Outs unclear, since all patients are noted to start guarana but drop-out occured for placebo)

• Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation  + (Disease progression n=1, patient decision n=1)

• Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy  + (Disease progression, unacceptable toxicity, or the patient’s refusal to continue the treatment No number was given for the individual reasons of Drop-outs)
• Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy  + (Disease progression, unacceptable toxicity, or the patient’s refusal to continue the treatment No number was given for the individual reasons of Drop-outs)
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (Dropped out (n=1); acute unrelated illness (n=2))
• Shapiro et al. (2016): Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)  + (Dropped out during run-in period)
• Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial  + (Due to side effects: n = 1, consent withdrawn: n = 5, difficulty swallowing capsule: n = 2, contact lost: n = 1)
• Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial  + (Due to side effects: n=3, consent withdrawn: n= 4, severe nausea / vomiting: n=1)
• Dörr et al. (2007): Efficacy of Wobe-Mugos E for Reduction of Oral Mucositis after Radiotherapy  + (Dysphagia before radiotherapy (n=1); change to palliative treatment (n=1); follow-up <2 weeks because of adverse events (n=1); lack of compliance/withdrawal of consent (n=1))
• Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study  + (Excluded due to changing chemotherapy (n=1))
• Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial  + (Finished the study prematurely at their own request)
• Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial  + (Finished the study prematurely at their own request)
• Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial  + (First phase: Revocation: 31x, Side effect … First phase: </br>Revocation: 31x, Side effects: 11x, Treatment refused: 10x, Deceased: 4x, Disease progression: 3x, Other: 3x</br></br>Second phase: </br>Treatment ended early: 28x, Side effects: 11x, Treatment refused: 9x, Deceased: 2x, Disease progression: 2x, Other: 4xed: 2x, Disease progression: 2x, Other: 4x)
• Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial  + (First phase: Revocation: 36x, Side effect … First phase: </br>Revocation: 36x, Side effects: 17x, Treatment refused: 13x, Deceased: 1x, Disease progression: 1x, Other: 4x</br></br>Second phase: </br>Treatment ended early: 29x, Side effects: 11x, Treatment refused: 5x, Deceased: 5x, Disease progression: 3x, Other: 4xed: 5x, Disease progression: 3x, Other: 4x)
• Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy  + (Forms not filled out correctly)
• Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy  + (Forms not filled out correctly)
• Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study  + (Frequent blood sampling; surgery; diabetes)
• Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer  + (Gastrointestonal side effects)
• Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects  + (Hepatitis (n=1); brain metastasis (n=1))
• Dörr et al. (2007): Efficacy of Wobe-Mugos E for Reduction of Oral Mucositis after Radiotherapy  + (Inability to swallow (n=1); follow-up <2 weeks because of adverse events (n=2); lack of compliance/withdrawal of consent (n=1))
• Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597  + (Ineligible (n = 10); No therapy (n = 12) … Ineligible (n = 10);</br>No therapy (n = 12)</br></br>Discontinued treatment:</br>Completed (n = 238);</br>Progression (n = 117);</br>Toxicity (n = 20);</br>Death (n = 18);</br>Withdrawal (n = 157);</br>Nonprotocol treatment (n = 1);</br>Complicating disease (n = 30);</br>Maximum dose (n = 2);</br>Other (n = 212)30); Maximum dose (n = 2); Other (n = 212))
• Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597  + (Ineligible (n = 6); No therapy (n = 2) Discontinued treatment: Completed (n = 134); Progression (n = 52); Toxicity (n = 8); Death (n = 12); Withdrawal (n = 67); Nonprotocol treatment (n = 3); Complicating disease (n = 17); Other (n = 105))
• Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group  + (Ineligible (n=12); never followed up cystoscopically (n=6))
• Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group  + (Ineligible (n=15); never followed up cystoscopically (n=6))
• Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer  + (Insufficient RNA quality or quantity (n=2))
• Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer  + (Insufficient RNA quality or quantity (n=6))
• Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer  + (Insufficient RNA quality or quantity (n=7))